Showing results (1601-1610 of 10,079) with videos related to
Sort By:
Pageof 1,008
Current Pharmaceutical Design|December 9, 2015
Jean-Baptiste de Sénac's (1693-1770) Important Work on Cardiology and Valvular DisordersMarianna Karamanou, Gregory Tsoucalas, Elias Gialafos, et al.Current Pharmaceutical Design|December 15, 2015
The Therapeutic Aspects of the Endocannabinoid System (ECS) for Cancer and their Development: From Nature to LaboratoryMohammed I Khan, Anna A Sobocińska, Anna M Czarnecka, et al.Current Pharmaceutical Design|December 15, 2015
Tryptophan Catabolites and MigraineZsuzsanna Bohár, Árpád Párdutz, László VécseiCurrent Pharmaceutical Design|December 15, 2015
Bipolar Disorder: The Role of the Kynurenine and Melatonergic PathwaysGeorge Anderson, Aude Jacob, Frank Bellivier, et al.Current Pharmaceutical Design|June 12, 2012
Neurobiology of depression and novel antidepressant drug targetsNikola Kern, Abigail J Sheldrick, Frank M Schmidt, et al.Current Pharmaceutical Design|June 12, 2012
Lack of data on depression-like states and antidepressant pharmacotherapy in patients with epilepsy: randomised controlled trials are badly neededKousuke Kanemoto, Yukari Tadokoro, Abigail J Sheldrick, et al.Current Pharmaceutical Design|June 12, 2012
Health service utilization and costs of depressive symptoms in late life - a systematic reviewMelanie Luppa, Claudia Sikorski, Tom Motzek, et al.Current Pharmaceutical Design|June 12, 2012
The Canadian Biomarker Integration Network in Depression (CAN-BIND): advances in response predictionSidney H Kennedy, Jonathan Downar, Kenneth R Evans, et al.Current Pharmaceutical Design|November 26, 2015
Neuroprotective Mechanisms Mediated by CDK5 InhibitionGohar Mushtaq, Nigel H Greig, Firoz Anwar, et al.Current Pharmaceutical Design|November 26, 2015
Psychopharmacology of Attention-Deficit Hyperactivity Disorder: Effects and Side EffectsJavad Golmirzaei, Hamidreza Mahboobi, Maryam Yazdanparast, et al.Pageof 1,008